Day: April 22, 2021

“Kinnevik started 2021 from a position of strength across our portfolio, and we continued to build on that platform during the first quarter. Our planned distribution of our shares in Zalando will enable Kinnevik to take a step-change in our strategic transformation, further increasing our focus on our younger growth portfolio.” Georgi Ganev, CEO of Kinnevik Key Strategic HighlightsWe proposed distributing Zalando to Kinnevik’s shareholders We participated with USD 30m in Cityblock’s funding round Material uplift in the valuation of Cedar in connection with the company’s USD 200m fundraise Material uplift in the valuation of VillageMD as a result of strong operational performance and expanding multiples We invested USD 70m into Vivino, the leading online wine marketplace and wine app Our NAV was negatively impacted by lower...

”Kinnevik startade 2021 med en genomgående stark position i vår portfölj och vi har fortsatt att bygga på den plattformen under det första kvartalet. Den planerade distributionen av våra aktier i Zalando gör det möjligt för Kinnevik att ta ett språngsteg i vår strategiska omvandling och ytterligare öka vårt fokus på vår yngre tillväxtportfölj.” Georgi Ganev, Kinneviks vd Viktiga strategiska händelserFöreslog att distribuera Zalando till Kinneviks aktieägare Deltog med 30 MUSD i en finansieringsrunda för Cityblock Materiell värdehöjning i Cedar till följd av en finansieringsrunda om 200 MUSD Materiell höjning i värderingen av VillageMD till följd av stark operationell utveckling och höjda multiplar Investerade 70 MUSD i Vivino, den ledande vinappen och marknadsplatsen för vin på nätet Substansvärdet påverkades negativt av lägre värderingar...

The Yara International ASA first quarter 2021 results will be published on Friday 23 April 2021 at 08:00 CEST. An on-line presentation will be held at 12:00 CEST, hosted by Yara President and CEO Svein Tore Holsether. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at:yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use this link for online registration for the conference call: http://emea.directeventreg.com/registration/9762459Participants must register in advance of the conference using the link provided. Upon registering, each participant will be provided with participant dial-in numbers, Direct Event passcode and unique...

Encouraging MultiClient SalesImproving Vessel Utilization Takeaways Q1 2021Segment Revenues and Other Income of $132.2 million, compared to $168.3 million in Q1 2020 Segment EBITDA of $84.1 million, compared to $80.5 million in Q1 2020 Segment EBIT (excluding impairments and other charges) loss of $13.9 million, compared to a loss of $15.8 million in Q1 2020 Segment MultiClient pre-funding revenues of $46.3 million, with a corresponding pre-funding level of 107%, compared to $40.7 million and 60%, respectively, in Q1 2020 Cash flow from operations of $88.6 million, compared to $176.0 million in Q1 2020   As Reported Revenues and Other Income according to IFRS of $165.7 million and an EBIT loss of $2.3 million, compared to $128.8 million and EBIT loss of $80.2 million, respectively, in Q1 2020 Awarded multiyear 4D framework agreement...

STOCKHOLM – April 22, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its first quarter results for 2021. The quarter saw strong and promising progress within digital pathology and the company’s first product, INIFY Prostate Screening. While the ongoing pandemic slowed sales slightly, solid financials – paired with close dialogues with present and prospective clients – provide a positive outlook. “Dr. Filippo Fraggetta – one of the leading pathologists in Europe and instrumental in the development of the product – confirms the preliminary results from the ongoing clinical study, indicating that using INIFY Prostate decreases variance between pathologists will benefit referrals and patients in the longer term. This...

STOCKHOLM – 22. april 2021 – ContextVision, et medisinsk teknologiselskap som spesialiserer seg på bildebehandling, bildeanalyse og beslutningsstøtteverktøy for digital patologi, legger i dag frem tallene for første kvartal 2021. Utviklingen innen digital patologi og selskapets første produkt, INIFY Prostate Screening, var sterkt gjennom kvartalet. Mens den pågående pandemien bremset salget litt, gjør selskapets sterke finansielle stilling – sammen med tette dialoger med nåværende og potensielle kunder – utsiktene særdeles positive. «Dr. Filippo Fraggetta – en av Europas ledende patologer, som også har vært medvirkende i utviklingen av INIFY Prostate – bekrefter resultatene fra de pågående kliniske studiene, som indikerer at bruk av INIFY Prostate reduserer variansen mellom patologer, som igjen vil være en fordel for henvisninger,...

Kesla Oyj:n liiketoimintakatsaus 1.1.-31.3.2021 KESLA OYJ, LIIKETOIMINTAKATSAUS         PÖRSSITIEDOTE 22.4.2021 klo 9.00 Q1/2021 (verrattuna Q1/2020) Konsernin liikevaihto laski ja liikevoitto heikkeni, mutta tilauskanta kasvoi merkittävästi. Valko-Venäjän pakotteet rajoittivat tuotantovolyymiä tammi-helmikuussa vaikuttaen kvartaalin kannattavuuteen.Konsernin liikevaihto laski 13,3 % vertailukaudesta ja oli 9,0 miljoonaa euroa (Q1/2020 10,4 miljoonaa euroa). Konsernin liikevoitto EBIT oli 109 tuhatta euroa tappiollinen (131 tuhatta euroa voitollinen). Liiketoiminnan rahavirta oli 837 tuhatta euroa positiivinen (1 411 tuhatta euroa). Konsernin tilauskanta oli kauden lopussa 14,5 miljoonaa euroa (10,4 miljoonaa euroa). Osakekohtainen tulos EPS oli -0,06 euroa (0,01 euroa) sekä A- että B-osakkeille.Keskeiset tunnusluvut, tilintarkastamattomia  1-3 1-3 1-121000...

Available in English onlyTotal income of EUR 11.9 million with an EBITDA of EUR 1.3 million Net result of EUR -0.3 million (after taxes) Cash flow from operating activities of EUR 1.5 millionDeventer, April 22, 2021 – RoodMicrotec N.V., a leading independent company for semiconductors supply and quality services, today published the Company’s Annual Report for the financial year 2020 including the audited financial statements. The complete 2020 Annual Report, which is available in English and only as an electronic version, is available on the corporate website: www.roodmicrotec.com/en/investor-relations-en/financial-publications. The total income for 2020 amounted to EUR 11.9 million, which was 10% lower than in 2019 but includes a substantial increase in the second half of 2020 (EUR 6.5 million) compared to the first half of 2020...